NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00146549,Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT00146549,,COMPLETED,"The purpose of this study is to compare two different combinations of chemotherapy with trastuzumab as initial treatment for HER2 positive advanced breast cancer. Half of the patients will receive trastuzumab in combination with a taxane form of chemotherapy (either paclitaxel or docetaxel), while the other group will receive trastuzumab in combination with vinorelbine.",NO,Breast Cancer|Stage IV Breast Cancer,DRUG: Trastuzumab|DRUG: Vinorelbine|DRUG: Paclitaxel|DRUG: Docetaxel,To compare the overall response rate for patients receiving trastuzumab in combination with either vinorelbine or taxane-based chemotherapy.,Characterization of the time to disease progression and time to treatment failure for patients receiving trastuzumab with either vinorelbine or taxane-based chemotherapy|Characterization of side effects for both treatments|analysis of quality of life for patients receiving either treatment.,,Dana-Farber Cancer Institute,Massachusetts General Hospital|Brigham and Women's Hospital|North Shore Medical Center|GlaxoSmithKline,ALL,"ADULT, OLDER_ADULT",PHASE3,250,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,01-087,2001-08,2007-08,2007-12,2005-09-07,,2009-11-01,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States",
